Antiarrhythmic efficacy of selective blockade of the cardiac slowly activating delayed rectifier current, I(Ks), in canine models of malignant ischemic ventricular arrhythmia

Circulation

Volumn 100, Issue 18, 1999, Pages 1917-1922

  Lynch Jr , Joseph J ^a   Houle, Melanie S ^b   Stump, Gary L ^b   Wallace, Audrey A ^b   Gilberto, David B ^b   Jahansouz, Hossain ^b   Smith, Garry R ^b   Tebben, Andrew J ^b   Liverton, Nigel J ^b   Selnick, Harold G ^b   Claremon, David A ^b   Billman, George E ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b NONE

Author keywords

Antiarrhythmia agents; Arrhythmia; Fibrillation; Myocardial infarction

Indexed keywords

2 [2,4 BIS(TRIFLUOROMETHYL)PHENYL] N [2,3 DIHYDRO 2 OXO 5 PHENYL 1 (2,2,2 TRIFLUOROETHYL) 1H BENZO[E][1,4]DIAZEPIN 3 YL]ACETAMIDE; ANTIARRHYTHMIC AGENT; L 768 673; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOG; DRUG EFFICACY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REFRACTORY PERIOD; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; QT INTERVAL;

EID: 0033517795     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.100.18.1917     Document Type: Article

References (31)

1. + current: differential sensitivity to block by class III antiarrhythmic agents. J Gen Physiol. 1990;96:195-215.
2. Wang Z, Fermini B, Nattel S. Rapid and slow components of delayed rectifier current in human atrial myocytes. Cardiovasc Res. 1994;28: 1540-1546.
3. + current in human ventricular myocytes. Circ Res. 1996;78:689-696.
4. Ks. Am J Physiol. 1996;271:H2477-H2489.
5. Ks play a role in the reverse rate dependence of class III agents? Circ Res. 1996;78:26-37.
6. Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ, Pauls JF, Pitt B, Pratt CM, Schwartz PJ, Veltri EP, for the SWORD Investigators. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet. 1996; 348:7-12.
7. Sager PT. New advances in class III antiarrhythmic drug therapy. Curr Opin Cardiol. 1999;14:15-23.
8. Kowey PR, Marinchak RA, Rials SJ, Bharucha D. Pharmacologic and pharmacokinetic profile of class III antiarrhythmic drugs. Am J Cardiol. 1997;80:16G-23G.
9. Ks by (R)-2-(2,4-trifluoromethyl)-N-[2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-2,3- dihydro-1H-benzo[e][1,4]diazepin-3-y1]-acetamide (L-768,673). J Med Chem. 1997;40:3865-3868.
10. Patterson E, Holland K, Eller BT, Lucchesi BR. Ventricular fibrillation resulting from ischemia at a site remote from previous myocardial infarction: a conscious canine model of sudden coronary death. Am J Cardiol. 1982;50:1414-1423.
11. Schwartz PJ, Billman GE, Stone HL. Autonomic mechanisms in ventricular fibrillation induced by myocardial ischemia during exercise in dogs with a healed myocardial infarction: an experimental preparation for sudden cardiac death. Circulation. 1984;69:780-790.
12. Billman GE, Englert HC, Scholkens BA. HMR 1883, a novel cardioselective inhibitor of the ATP-sensitive potassium channel, II: effects on susceptibility to ventricular fibrillation induced by myocardial ischemia in conscious dogs. J Pharmacol Exp Ther. 1998;286:1465-1473.
13. Lynch JJ Jr, Wallace AA, Stump GL, Stupienski RF III, Kothstein T, Gehret JR. Differential efficacy of the class III agent MK-499 against programmed stimulation-induced and ischemic-induced ventricular arrhythmias in a canine model of previous myocardial infarction. J Pharmacol Exp Ther. 1996;277:671-678.
14. + current is composed of two currents in guinea pig atrial cells. Am J Physiol. 1991;260:H393-H399.
15. + current by dofetilide. Circ Res. 1993;72:75-83.
16. Hondeghem LM, Snyders DJ. Class III antiarrhythmic agents have a lot of potential, but a long way to go: reduced effectiveness and dangers of reverse use-dependence. Circulation. 1990;81:686-690.
17. Sanguinetti MC, Jurkiewicz NK, Scott A, Siegl PKS. Isoproterenol antagonizes prolongation of refractory period by the class III antiarrhythmic agent E-4031 in guinea pig myocytes. Circ Res. 1991;68:77-84.
18. Schreieck J, Wang Y, Gjini V, Korth M, Zrenner B, Schömig A, Schmitt C. Differential effect of β-adrenergic stimulation on the frequency-dependent electrophysiologic actions of the new class III antiarrhythmics dofetilide, ambasilide, and chromanol 293B. J Cardiovasc Electrophysiol. 1997;8:1420-1430.
19. + channel blockade in the prevention of ventricular fibrillation in dogs with acute ischemia and enhanced sympathetic activity. J Cardiovasc Pharmacol. 1995;26:847-854.
20. Schwartz PJ. Do animal models have clinical relevance? Am J Cardiol. 1998;81:14D-20D.
21. Ks in guinea pig cardiac myocytes and guinea pig IsK channels by the chromanol 293B. Pflugers Arch. 1996;432:1094-1096.
22. Loussouarn G, Charpentier F, Mohammad-Panah R, Kunzelmann K, Baro I, Escande D. KvLQT1 potassium channel but not IsK is the molecular target for trans-6-cyano-4-(N-ethylsulfonyl-N-methylamino)-3-hydroxy-2.2-dimethyl-chromane. Mol Pharmacol. 1997;52:1131-1136.
23. + current, on repolarization in human and guinea pig ventricular myocytes. Cardiovasc Res. 1998;38:441-450.
24. Ks. Circulation. 1997;96(suppl I):I-292. Abstract.
25. Ks block promotes β adrenergic agonist-induced delayed afterdepolarization activity in canine ventricular myocardium. Circulation. 1997;96(suppl I):I-293. Abstract.
26. Shimizu W, Antzelevitch C. Cellular basis for the ECG features of the LQT1 form of the long QT syndrome: effects of β-adrenergic agonists and antagonists and sodium channel blockers on transmural dispersion of repolarization and torsade de pointes. Circulation. 1998;98:2314-2322.
27. Lynch JJ, Wilber DJ, Montgomery DG, Hsieh TM, Patterson E, Lucchesi BR. Antiarrhythmic and antifibrillatory actions of the levo-and dextrorotatory isomers of sotalol. J Cardiovasc Pharmacol. 1984;6:1132-1141.
28. Katoh H, Ogawa S, Furuno I, Sato Y, Yoh S, Saeki K, Nakamura Y. Electrophysiologic effects of E-4031, a class III antiarrhythmic agent, on re-entrant ventricular arrhythmias in a canine 7-day-old myocardial infarction model. J Pharmacol Exp Ther. 1990;253:1077-1082.
29. Black SC, Chi L, Mu D-X, Lucchesi BR. The antifibrillatory actions of UK-68,798, a class III antiarrhythmic agent. J Pharmacol Exp Ther. 1991;258:416-423.
30. Ackerman MJ. The long QT syndrome: ion channel diseases of the heart. Mayo Clin Proc. 1998;73:250-269.
31. Schwartz PJ, Matteo PS. Moss AJ, Priori SG, Wang Q, Lehmann MH, Timothy K, Denjoy IF, Haverkamp W, Guicheney P, Paganini V, Scheinman MM, Karnes PS. Gene-specific influence on the triggers for cardiac arrest in the long QT syndrome. Circulation. 1997;96(suppl I):I-212. Abstract.